张小虎 - 苏州大学 - 医学部药学院

个人简介

学历背景 1986.9-1990.6：北京大学，理学学士 1992.9-1997.11：Rutgers University，美国新泽西州立大学，博士工作经历 1990.8-1992.7：内蒙古金属材料研究所，工程师 1998.3-1999.6：Chromagen Inc., San Diego, CA, USA. 研究员 1999.6-2000.10：Stratagene，an Agilent company，研究员，项目经理 2000.10-2008.2：Neurocrine Biosciences，资深研究员 2008.3-2012.4：BioDuro，a PPD company,北京，总监，资深总监，执行总监 2012.4-至今：苏州大学药学院，特聘教授

研究领域

（1）靶向中枢神经系统重大疾病的药物研发：以帕金森氏病、抑郁症、药物成瘾为靶向，寻找和发现新型小分子药物。（2）新型抗肿瘤药物的研发：专注于胚胎通路（刺猬通路拮抗剂，豪猪蛋白拮抗剂等）的候选药物研发。

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Development of Adenosine A2A Receptor Antagonists for the Treatment of Parkinson's Disease: A Recent Update and Challenge. Zheng, J.; Zhang, X.* Zhen, X.* ACS Chem. Neurosci. 2019, 10, 783-791. Discovery of potent and novel smoothened antagonists via structure-based virtual screening and biological assays. Lu, W.; Zhang, D.; Ma, H. *; Tian, S. *; Zheng, J.; Wang, Q.; Luo, L.; Zhang, X.*Eur. J. Med. Chem. 2018,155, 34-48. A novel hedgehog inhibitor for the treatment of hematological malignancies. Lin, P; He, Y.; Chen, G.; Ma, H.; Zheng, J.; Zhang, Z.; Cao, B.; Zhang, H.; Zhang, X.; and Mao, X. Anti-Cancer Drugs. 2018, 29:995–1003. Discovery of a potent hedgehog pathway inhibitor capable of activating caspase8-dependent apoptosis. Chen, Q.; Zhang, H.; Wu, M.; Wang, Q.; Luo, L.; Ma, H.; * Zhang, X.; * He, S. * Journal of Pharmacological Sciences. 2018, 137, 256-264. Discovery and characterization of a potent Wnt and hedgehog signaling pathways dual inhibitor. Ma, H.; Chen, Q.; Zhe, F.; Zheng, J.*; Li, J.; Zhang, H.; Chen, S.; Xing, H.; Luo, L.; Zheng, L.; He, S.*; Zhang, X.* Eur. J. Med. Chem. 2018,149, 110-121. Design, Synthesis, and Structure-Activity-Relationship of a Novel Series of CXCR4 Antagonists Li, Z.; Wang, Y.; Fu, C.; Wang, X.; Wang, J.J.; Zhang, Y.; Zhou, D.; Zhao, Y.; Luo, L.*; Ma, H.; Lu, W.; Zheng, J.*; Zhang, X.* Eur. J. Med. Chem. 2018,149, 30-44. Design, Synthesis, and Structure−Activity Relationship of Tetrahydropyrido[4,3d]pyrimidine Derivatives as Potent Smoothened Antagonists with in Vivo Activity. Lu, W.; Liu, Y.; Ma, H.; Zheng, J.; Tian, S.; Sun, Z.; Luo, L.*; Li, J.; Zhang, H.; Yang, Z-J.*; Zhang, X.* ACS Chem. Neurosci. 2017, 8, 1980-1994. GYY4137, an H2S Slow-Releasing Donor, Prevents Nitrative Stress and a-Synuclein Nitration in an MPTP Mouse Model of Parkinson’s Disease. Hou, X.; Yuan, Y.; Sheng, Y.; Yuan, B.; Wang, Y.; Zheng, J.; Liu, C-F.; Zhang, X.*; Hu, L.* Front. Pharmacol. 2017, 8:741. Discovery of Novel and Selective Adenosine A2A Receptor Antagonists for Treating Parkinson’s Disease through Comparative Structure-Based Virtual Screening. Tian, S.; Wang, X.; Li, L.; Zhang, X.; Li, Y.; Zhu, F.; Hou, T.*; Zhen, X.* J. Chem. Inf. Model. 2017, 57, 1474-1487. Antiviral activity of PHA767491 against human herpes simplex virus in vitro and in vivo. Hou, J.; Zhang, Z.; Huang, Q.; Yan, J.; Zhang, X.; Yu, X.; Tan, G.; Zheng, C.; Xu, F.*; He, S.* BMC Infectious Disease. 2017, 17: 217. Identification of a New Series of Potent Adenosine A2A Receptor Antagonists Based on 4-Amino-5-carbonitrile Pyrimidine Template for the Treatment of Parkinson's Disease. Yang, Z; Li, L; Zheng, J; Ma, H; Tian, S; Li, J; Zhang, H; Zhen, X;* Zhang, X.* ACS Chem. Neurosci. 2016, 7, 1575-1584. Design, synthesis, and evaluation of novel porcupine inhibitors featuring a fused 3-ring system based on the 'reversed' amide scaffold. Xu, Z; Xu, X; O'Laoi, R; Ma, H; Zheng, J;* Chen, S; Luo, L;* Hu, Z; He, S; Li, J; Zhang, H; Zhang, X.* Bioorg. Med. Chem. 2016, 24, 5861-5872. Design, synthesis, and evaluation of potent Wnt signaling inhibitors featuring a fused 3-ring system. Xu, Z.; Li, J.; Wu, Y.; Sun, Z.; Luo, L.*; Hu, Z.; He, S.; Zheng, J.*; Zhang, H.; Zhang, X.* Eur. J. Med. Chem. 2016,108, 154-165. Exploration of the linkage elements of porcupine antagonists led to potent Wnt signaling pathway inhibitors. Dong, Y.; Li, K.; Xu, Z.; Ma, H.; Zheng, J.; Hu, Z.; He, S.; Wu, Y.; Sun, Z.; Luo, L.; Li, J.; Zhang, H.; Zhang, X.*Bioorg. Med. Chem. 2015,23, 6855-6868. Discovery of a 6-(pyridin-3-yl)benzo[d]thiazole template for optimization of hedgehog and PI3K/AKT/mTOR dual inhibitors, Yang, Z.; Ma, H.; Sun, Z.; Luo, L.; Tian, S.; Zheng, J.;Zhang, X.*Bioorg. Med. Chem. Lett. 2015,25, 3665-3670. Design, synthesis and evaluation of a series of non-steroidal anti-inﬂammatory drug conjugates as novel neuroinﬂammatory inhibitors. Xu, Z.; Wu, J.; Zheng, J.; Ma, H.; Zhang, H.; Zhen, X.; Zheng, L.*; Zhang, X.* International Immunopharmacology. 2015, 25(2), 528-537. Anti-inflammatory effects of glaucocalyxin B in microglia cells. Gan, P.; Zhang, L.; Chen, Y.; Zhang, Y.; Zhang, F.; Zhou, X.; Gao, B.; Zhen, X.; Zhang, X.; Zhang, J.; Zheng, L.* Journal of Pharmacological Sciences. 2015, 128(1), 35-46. Design, synthesis, and structure-activity-relationship of tetrahydrothiazolopyridine derivatives as potent smoothened antagonists. Ma, H.; Lu, W.; Sun, Z.; Luo L. *; Geng, D.; Yang, Z.; Li E.; Zheng, J.; Wang, M.; Zhang, H.; Yang, S.; Zhang, X.* EuropeanJournal of Medicinal Chemistry. 2015, 89, 721-732. Optimization of 6-heterocyclic-2-(1H-pyrazol-1-yl)-N-(pyridin-2-yl) pyrimidin-4-amine as potent adenosine A2A receptor antagonists for the treatment of Parkinson ’s disease. Zheng, J.; Yang, Z.; Li, X.; Li, L.; Ma, H.; Wang, M.; Zhang, H.; Zhen, X.*; Zhang, X.* ACS Chemical Neuroscience. 2014, 5, 674-682. Scaffold hopping approach to a new series of smoothened antagonists. Lu, W.; Geng, D.; Sun, Z.; Yang, Z.; Ma, H.; Zheng, J., Zhang, X.* Bioorg. Med. Chem. Lett. 2014, 24, 2300-2304.